Catalogo dei prodotti della ricerca

MILLEFIORINI, Enrico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.740
EU - Europa 1.045
AS - Asia 604
SA - Sud America 21
AF - Africa 9
OC - Oceania 4
Totale 5.423
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.713
IT - Italia 329
SG - Singapore 261
SE - Svezia 191
IN - India 175
CN - Cina 144
UA - Ucraina 128
FI - Finlandia 125
DE - Germania 115
RU - Federazione Russa 35
GB - Regno Unito 30
BG - Bulgaria 25
CA - Canada 21
AR - Argentina 17
IE - Irlanda 14
RO - Romania 12
BE - Belgio 9
ID - Indonesia 9
CZ - Repubblica Ceca 6
FR - Francia 5
HK - Hong Kong 5
MX - Messico 5
AU - Australia 4
LT - Lituania 4
NL - Olanda 4
TG - Togo 4
CH - Svizzera 3
MK - Macedonia 3
BR - Brasile 2
DZ - Algeria 2
ES - Italia 2
GR - Grecia 2
IL - Israele 2
IR - Iran 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AT - Austria 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
EG - Egitto 1
IQ - Iraq 1
PA - Panama 1
RS - Serbia 1
SA - Arabia Saudita 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 5.423
Salva come PNG Salva come JPEG
Città #
Fairfield 609
Woodbridge 355
Ashburn 286
Chandler 230
Seattle 229
Houston 210
Singapore 202
Wilmington 197
Cambridge 190
Ann Arbor 145
Princeton 117
Rome 116
Plano 85
Dearborn 79
San Paolo di Civitate 73
Santa Clara 69
Beijing 66
Lawrence 60
Boston 57
Des Moines 50
Jacksonville 48
Helsinki 46
San Diego 41
Norwalk 30
Andover 26
Millbury 25
Sofia 25
New York 20
Federal 17
Boardman 16
Dublin 14
Moscow 14
Milan 13
Toronto 13
Falls Church 12
Fasano 12
Munich 11
Brussels 9
Bühl 9
Hefei 8
Jakarta 8
Nanjing 8
Fremont 7
Grafing 7
Brno 6
Auburn Hills 5
Hong Kong 5
Indiana 5
San Mateo 5
Bari 4
Falkenstein 4
Jinan 4
Lomé 4
London 4
Mannheim 4
Mexico City 4
Nanchang 4
Ottawa 4
Phoenix 4
Venezia 4
Albano Laziale 3
Kunming 3
Martellago 3
Salerno 3
Sheffield 3
Skopje 3
Stockholm 3
Taiyuan 3
Turin 3
Zhengzhou 3
Algiers 2
Bern 2
Bonndorf 2
Catania 2
Changsha 2
Chengdu 2
Conegliano 2
Fuzhou 2
Guangzhou 2
Hyderabad 2
Jerusalem 2
Laurel 2
Marigliano 2
Montréal 2
Morlupo 2
Mountain View 2
Newark 2
Oakland 2
Oyster Bay 2
Philadelphia 2
Pomezia 2
Sezze 2
Shanghai 2
Silverton 2
Southend 2
Staten Island 2
São Paulo 2
Taranto 2
Thessaloniki 2
Tower Hamlets 2
Totale 4.024
Salva come PNG Salva come JPEG
Nome #
Deep grey matter involvement and altered sensory gating in multiple sclerosis 115
A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis 113
Lead poisoning during heroin addiction 105
Mechanisms of pain in multiple sclerosis: A combined clinical and neurophysiological study 104
Computerized color perimetry in multiple sclerosis 103
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 103
Increased circulating levels of vitamin D binding protein in MS patients 98
Involvement of the limbic system in multiple sclerosis patients with depressive disorders 94
Trigeminal neuralgia and pain related to multiple sclerosis. 91
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis. An Italian, Multicenter, Real-World Study 88
La neurologia della Sapienza 87
Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. 87
Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis - Results of the BetaPlus observational cohort study 85
Campimetria cromatica nella sclerosi multipla 84
Exit strategies for "needle fatigue" in multiple sclerosis: a propensity score-matched comparison study 84
Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. 83
Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. 82
Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis 82
BETA2-MICROGLOBULIN SERUM LEVEL IS NOT A MARKER OF DISEASE ACTIVITY IN MULTIPLE SCLEROSIS 81
A controlled study of potential risk factors preceding exacerbation in multiple sclerosis. 80
Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. 80
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis 79
Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation 79
Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment 78
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 75
Fingolimod vs dimethyl fumarate in multiple sclerosis. a real-world propensity score-matched study 75
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases 74
Mitochondrial Genome Profile in Demyelinating Diseases 73
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 73
Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. 72
Circadian variation in the onset of acute cerebral ischemia: ethiopathogenetic correlates in 80 patients given angiography. 72
Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by rebiject autoinjection over a 1-year period: The CoSa study 70
Photophobia in multiple sclerosis 70
Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study 70
Expression of biomarkers of interferon type I in patients suffering from chronic diseases 67
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 66
An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis 66
Fatigue in MS is associated with specific clinical features. 65
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. 64
Involvement of the limbic system in multiple sclerosis patients with depressive disorders. 63
Effect of stress on cardiovascular regulation in neurological diseases with dysautonomia. 62
Influenza immunization in multiple sclerosis 62
Cortical M1 plasticity and metaplasticity in patients with multiple sclerosis 62
null 60
Cardiac autonomic dysfunction in relapsing-remitting multiple sclerosis during a stable phase 60
Brain atrophy in relasping-remitting multiple sclerosis:relationship with "black holes", disease duration and disability 59
Invasive treatment of acute stroke. 58
Interferon beta-1a in relapsing-remitting multiple sclerosis:effect on hypointense lesion volume on T1-weighted images 58
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society 57
null 57
FATIGUE IN MS IS ASSOCIATED WITH SPECIFIC CLINICAL-FEATURES 55
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS 54
Altered sensorimotor integration in multiple sclerosis: A combined neurophysiological and functional MRI study 54
Proteolytic balance in patients with multiple sclerosis during interferon treatment 53
Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers 53
INVASIVE TREATMENT OF ACUTE STROKE 52
the prevalence of ms in central italy 49
The influence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. 49
null 49
null 49
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 48
Lack of association between macrocytosis and multiple sclerosis. 48
Duloxetine for the Treatment of Overactive Bladder Syndrome in Multiple Sclerosis: A Pilot Study 48
Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab 47
Detection of human herpesviruses and polyomaviruses DNA in a group of patients with relapsing-remitting multiple sclerosis 46
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 46
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. 46
null 45
Subclinical peripheral nervous system involvement in multiple sclerosis 44
Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. 43
ccl2 induction by 1,25 (oh)2d3 in debdritic cells from healty donors and ms patients 42
Evolution and severity markers in 233 MS patients. 42
Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. 42
Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients 41
Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. 41
A longitudinal study in multiple sclerosis 37
Fattori prognostici in pazienti con sclerosi multipla di tipo recidivante-remittente. Studio longitudinale di 3 anni. 34
null 33
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis 32
Possibile ruolo delle infezioni virali nell’eziopatogenesi della sclerosi multipla: indagine su un gruppo di pazienti con SM remittente 32
short-term brain atrophy changes in r-r multiple sclerosis 31
Sclerosi Multipla 31
Controlled clinical trials in stroke. 30
Opposite regulatory effects of IFN-β and IL-3 on C-type lectin receptors, antigen uptake, and phagocytosis in human macrophages 24
Viral infections and multiple sclerosis: research on remittent-relapsing MS patients. 24
Prognostic indicators in pediatric clinically isolated syndrome 24
Subclinical peripheral nervous system involvement in multiple sclerosis. 23
Prognosi precoce nella paralisi di Bell in base a rilievi clinico neurofisiologici standardizzati 22
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 19
Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations. 19
natalizumab therapy of ms study group 18
Somatosensory temporal discrimination threshold is impaired in patients with multiple sclerosis 18
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 17
the global adherence project a multicenter observation study on adherence to disease-modifying therapies in patients with rr-ma. 14
Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis. 14
The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis 13
Intradetrusorial botulinum toxin in patients with multiple sclerosis: A neurophysiological study 13
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 10
OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results 2
Totale 5.595
Salva come PNG Salva come JPEG
Categoria #
all - tutte 15.608
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 15.608
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020864 0 0 0 0 0 183 175 159 141 104 68 34
2020/2021448 47 49 21 37 4 29 33 42 41 97 38 10
2021/20221.002 6 58 77 45 143 42 26 101 70 79 166 189
2022/2023978 219 197 49 74 93 117 31 45 99 5 40 9
2023/2024427 20 54 17 24 36 53 19 40 2 52 52 58
2024/2025445 59 84 67 47 91 97 0 0 0 0 0 0
Totale 5.595